NCT07588230 Serratus Posterior Superior Intercostal Plane Block in Minimally Invasive Cardiac Surgery
| NCT ID | NCT07588230 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital |
| Condition | Heart Valve Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-05-16 |
| Primary Completion | 2026-10-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2026-05-16 with a primary completion date of 2026-10-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized, double-blind, placebo-controlled study aims to evaluate the effect of the serratus posterior superior intercostal plane (SPSIP) block on postoperative pain and opioid consumption in patients undergoing minimally invasive cardiac valve surgery via mini-thoracotomy.
Eligibility Criteria
Inclusion Criteria: * Adult patients aged 18-75 years * ASA physical status I-III * Scheduled for elective minimally invasive cardiac valve surgery via mini-thoracotomy * Able to understand and use the Numeric Rating Scale (NRS) * Provided written informed consent Exclusion Criteria: * Age \>75 years * Known allergy or hypersensitivity to local anesthetics (e.g., bupivacaine) * Coagulopathy or ongoing anticoagulant therapy that cannot be discontinued * Infection at the planned block site * Chronic opioid use or chronic pain conditions * Severe pulmonary disease affecting respiratory assessment * Neurological or psychiatric disorders interfering with pain assessment * Emergency surgery * Pregnancy or breastfeeding * Refusal to participate
Contact & Investigator
Fatma Acil, M.D.
PRINCIPAL INVESTIGATOR
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
Frequently Asked Questions
Who can join the NCT07588230 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Heart Valve Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07588230 currently recruiting?
Yes, NCT07588230 is actively recruiting participants. Contact the research team at acilfatma@gmail.com for enrollment information.
Where is the NCT07588230 trial being conducted?
This trial is being conducted at Diyarbakır, Turkey (Türkiye).
Who is sponsoring the NCT07588230 clinical trial?
NCT07588230 is sponsored by Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital. The principal investigator is Fatma Acil, M.D. at Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital. The trial plans to enroll 90 participants.